


MM 07

Chemical Properties

CAS No. : 1876450-21-3
 Formula: C₆₇H₁₀₆N₂₂O₁₄S₃
 Molecular Weight: 1539.9
 Storage: Keep away from moisture
 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	Apelin biased agonist; exhibits bias for the G protein pathway. Stimulates endothelial NOS phosphorylation and expression, promotes proliferation, and attenuates apoptosis of human pulmonary arterial endothelial cells in vitro. Shows positive inotropic and vasodilatory effects in vivo and improves cardiac structure and function in a model of pulmonary arterial hypertension.
Targets(IC50)	Apelin receptor

Solubility Information

Solubility	H ₂ O: 2 mg/mL (1.3 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.6494 mL	3.247 mL	6.4939 mL
5 mM	0.1299 mL	0.6494 mL	1.2988 mL
10 mM	0.0649 mL	0.3247 mL	0.6494 mL
50 mM	0.013 mL	0.0649 mL	0.1299 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Brame et al (2015) Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 65 834 PMID:

Yang et al (2019) A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br.J.Pharmacol. 176 1206 PMID:

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481